Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

Key Takeaways MRK will report Q2 results on July 29. Consensus estimates for sales are at $15.77B and EPS at $1.99.Keytruda, Lynparza and new drugs like Capvaxive are expected to boost Q2 pharmaceutical sales.Weak Gardasil demand in China, generic erosion and pipeline reliance may weigh on investor sentiment.Merck (MRK) will report its second-quarter 2025 earnings on July 29, before market open. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $15.77 billion and $1.99 per shar ...